Veracyte Inc
$ 33.51
0.18%
21 Apr - close price
- Market Cap 2,662,652,000 USD
- Current Price $ 33.51
- High / Low $ 34.63 / 33.29
- Stock P/E 40.87
- Book Value 16.50
- EPS 0.82
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.05 %
- 52 Week High 50.71
- 52 Week Low 22.61
About
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
Analyst Target Price
$46.55
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-04 | 2025-08-06 | 2025-05-05 | 2025-02-20 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-08 | 2023-05-04 |
| Reported EPS | 0.53 | 0.51 | 0.44 | 0.31 | 0.36 | 0.19 | 0.07 | -0.02 | -0.39 | -0.41 | -0.12 | -0.11 |
| Estimated EPS | 0.39 | 0.32 | 0.11 | -0.17 | 0.2571 | 0.03 | -0.02 | -0.16 | -0.09 | -0.15 | -0.15 | -0.13 |
| Surprise | 0.14 | 0.19 | 0.33 | 0.48 | 0.1029 | 0.16 | 0.09 | 0.14 | -0.3 | -0.26 | 0.03 | 0.02 |
| Surprise Percentage | 35.8974% | 59.375% | 300% | 282.3529% | 40.0233% | 533.3333% | 450% | 87.5% | -333.3333% | -173.3333% | 20% | 15.3846% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VCYT
2026-04-21 05:39:11
The liquid biopsy for cancer diagnostics market is projected to reach $22.99 billion by 2030, driven by increased integration into cancer screening, personalized treatment, and investments in diagnostic technologies. Key trends include the use of liquid biopsy for lung cancer, blood-based screening, and real-time cancer tracking. The market is also seeing strategic acquisitions and technological advancements aimed at faster and more efficient diagnostics.
2026-04-17 00:09:28
Veracyte (VCYT) has seen a recent share price rebound despite mixed longer-term performance, trading at a significant discount to analyst targets and intrinsic value estimates. While a narrative suggests it's undervalued at $47.00 based on strong growth in diagnostics, its high P/E ratio of 41.1x compared to industry averages indicates potential valuation risk. Investors are advised to conduct their own due diligence, stress-test assumptions, and consider broader market opportunities in healthcare.
2026-04-16 09:10:07
Sumitomo Mitsui Trust Group Inc. has reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 15.1% in the fourth quarter, selling 224,185 shares and now holding 1,257,898 shares valued at $52.96 million. This follows recent insider selling by Veracyte's CEO and CFO. Despite a mixed analyst outlook (consensus "Hold" rating with a $44.33 target price), Veracyte exceeded Q4 earnings expectations with EPS of $0.53 and revenue of $140.6 million.
2026-04-15 08:09:39
Veracyte, Inc. announced that it will release its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss these results and provide a business update. Veracyte is a global diagnostics company focused on transforming cancer care through its high-performing cancer tests.
2026-04-14 23:09:39
Veracyte, a prominent cancer diagnostics company, announced it will release its first-quarter 2026 financial results after market close on Tuesday, May 5, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss these results and provide a business update. This report is highly anticipated by investors and analysts for insights into the company's growth, market share, and the adoption of its diagnostic tests within the cancer diagnostics industry.
2026-04-14 21:40:35
Veracyte, a leading cancer diagnostics company, will release its first-quarter 2026 financial results after market close on Tuesday, May 5, 2026. This will be followed by a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Investors and analysts closely monitor these reports to assess Veracyte's performance and growth trajectory in the cancer diagnostics market.
